TY - JOUR
T1 - Developments in care for patients with pancreatic cancer
AU - Augustinus, Simone
AU - Busch, Olivier R.
AU - Bonsing, Bert A.
AU - Bruno, Marco J.
AU - de Groot, Jan Willem B.
AU - Groot Koerkamp, Bas
AU - Intven, Martijn P.W.
AU - Köhler, Frank
AU - Molenaar, Quintus
AU - Wilmink, Johanna W.
AU - Besselink, Marc G.
N1 - Publisher Copyright:
© 2023, Bohn Stafleu van Loghum. All rights reserved.
PY - 2023/11/20
Y1 - 2023/11/20
N2 - In the past years several developments have occurred in the care for patients with pancreatic cancer in the Netherlands. New palliative chemotherapy strategies using FOLFRINOX or gemcitabine/nab-paclitaxel were introduced for patients with advanced disease. Due to centralization of pancreatic surgery, introduction of neoadjuvant therapy, and the implementation of standardized postoperative care more patients became enable for resection, postoperative mortality decreased, and survival improved. Within the randomized PREOPANC trial of the Dutch Pancreatic Cancer Group (DPCG), neoadjuvant therapy using chemoradiation for (borderline) resectable pancreatic cancer improved five-year survival from 7% to 21%. Furthermore, due to nationwide training programs, the use of minimally invasive surgery has increased. Regardless of these developments, the survival of patients with pancreatic cancer is still low and 61% of Dutch patients with pancreatic cancer patients do not receive any tumor targeted therapy. The DPCG is active to improve quality of care through auditing, research, guideline development, and education.
AB - In the past years several developments have occurred in the care for patients with pancreatic cancer in the Netherlands. New palliative chemotherapy strategies using FOLFRINOX or gemcitabine/nab-paclitaxel were introduced for patients with advanced disease. Due to centralization of pancreatic surgery, introduction of neoadjuvant therapy, and the implementation of standardized postoperative care more patients became enable for resection, postoperative mortality decreased, and survival improved. Within the randomized PREOPANC trial of the Dutch Pancreatic Cancer Group (DPCG), neoadjuvant therapy using chemoradiation for (borderline) resectable pancreatic cancer improved five-year survival from 7% to 21%. Furthermore, due to nationwide training programs, the use of minimally invasive surgery has increased. Regardless of these developments, the survival of patients with pancreatic cancer is still low and 61% of Dutch patients with pancreatic cancer patients do not receive any tumor targeted therapy. The DPCG is active to improve quality of care through auditing, research, guideline development, and education.
UR - http://www.scopus.com/inward/record.url?scp=85177833268&partnerID=8YFLogxK
M3 - Article
C2 - 37994711
AN - SCOPUS:85177833268
SN - 0028-2162
VL - 167
JO - Nederlands Tijdschrift voor Geneeskunde
JF - Nederlands Tijdschrift voor Geneeskunde
IS - 47
M1 - D7435
ER -